Intravitreal Injection of Ozurdex as a Primary Mode of Treatment in Diabetic Macular Edema - One Year Follow Up

One of the leading causes of visual loss in diabetic patients with retinopathy is macular edema. Accumulation of fluid in the retinal layers causes disruption of blood retinal barrier in patients with diabetic macular edema. AIM: To evaluate the efficacy and safety of intravitreal dexamethasone implant Ozurdex in Diabetic macular edema. OBJECTIVE: To measure for best corrected visual acuity using ETDRS pre and post Ozurdex implant injection. RESULT: Our study demonstrates the efficacy and safety profile of the intravitreal dexamethasone implant with one year time frame. Our findings also suggest that patients with dexamethasone implant showed maximum efficacy at 3 months which then declined progressively, but is still better than baseline values at the end of follow-up, although individual response and metabolic state of the patient should be strictly monitored.